ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

ClinicalTrials.gov ID: NCT00478426

Public ClinicalTrials.gov record NCT00478426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma

Study identification

NCT ID
NCT00478426
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
34 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2007
Primary completion
Feb 11, 2019
Completion
Feb 11, 2019
Last update posted
Feb 16, 2020

2007 – 2019

United States locations

U.S. sites
21
U.S. states
7
U.S. cities
20
Facility City State ZIP Site status
Tower Cancer Research Foundation Beverly Hills California 90211
City of Hope Comprehensive Cancer Center Duarte California 91010
USC / Norris Comprehensive Cancer Center Los Angeles California 90033
University of California Davis Comprehensive Cancer Center Sacramento California 95817
City of Hope South Pasadena South Pasadena California 91030
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
Decatur Memorial Hospital Decatur Illinois 62526
Evanston Hospital CCOP Evanston Illinois 60201
Ingalls Memorial Hospital Harvey Illinois 60426
Joliet Oncology-Hematology Associates Limited Joliet Illinois 60435
Loyola University Medical Center Maywood Illinois 60153
Illinois CancerCare-Peoria Peoria Illinois 61615
Central Illinois Hematology Oncology Center Springfield Illinois 62702
Southern Illinois University School of Medicine Springfield Illinois 62702
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne Indiana 46804
Northern Indiana Cancer Research Consortium South Bend Indiana 46628
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Oncology Care Associates PLLC Saint Joseph Michigan 49085
Mercy Hospital Saint Louis St Louis Missouri 63141
Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00478426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2020 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00478426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →